ZA200705708B - A composition - Google Patents
A composition Download PDFInfo
- Publication number
- ZA200705708B ZA200705708B ZA200705708A ZA200705708A ZA200705708B ZA 200705708 B ZA200705708 B ZA 200705708B ZA 200705708 A ZA200705708 A ZA 200705708A ZA 200705708 A ZA200705708 A ZA 200705708A ZA 200705708 B ZA200705708 B ZA 200705708B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- humic acid
- oils
- administered
- medicament
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 27
- 239000003921 oil Substances 0.000 claims description 16
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 claims description 15
- 239000004021 humic acid Substances 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 4
- 240000002657 Thymus vulgaris Species 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000001585 thymus vulgaris Substances 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229960003104 ornithine Drugs 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 claims 2
- 240000007926 Ocimum gratissimum Species 0.000 claims 2
- HDWLUGYOLUHEMN-UHFFFAOYSA-N Dinobuton Chemical compound CCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1OC(=O)OC(C)C HDWLUGYOLUHEMN-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000002391 femur head Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Description
I
A COMPOSITION
The invention relates to a composition which will assist operation of the immune system.
In the wake of new biological discoveries and molecular developments, which at the time were thought to be to the benefit of mankind, there are now a number of problems that have been found. With the production of seemingly any new molecules, it was thought that we could manipulate life. The associated problems have impacted on the ecological environment, by causing a deviation from normal biological processes, as well as the immune response processes of animals and humans. The negative side effects on biological processes appear significant. This is particularly the case with domestic animals raised for human consumption on supplements, such as growth stimulants and medicaments, including antibiotics. Chickens are one example of such animals. In this case, the birds are affected by a syndrome characterized by deficient immune system response.
The syndrome referred to is complex in chickens and is first triggered by the vertical transmission of pathogenic bacteria to the egg yolk as it travels down the Co
Eg Wo oviduct before it is covered by the cuticle. During incubation and in the whole embryonic development stage all new dividing cells are subjected to these bacteria. This is also the case with the evolving immune system. These bacterial cells are now seen as “normal self biological cells” and this sets the platform for acquiring tolerance to these bacteria. For the rest of the animal's lifespan it will not be able to launch an immune response to this pathogen and is now an active carrier of this disease.
Throughout the whole process these bacteria keep their capsules intact without revealing there surface antigenic determinants. This is why these cells coupled to the la Antigen, a receptor on the membrane surface, can pass through the cytoplasmic membrane of the macrophages and lie dormant in the cytoplasm without any danger of phagasome and lisosomatic digestion.
During any form of stress, especially associated with factors that suppress the immune system, these bacteria shed their capsules and become active. They leave the macrophage cells and adhere again to cells with the la Antigen, in this case B lymphocytes and all red blood cells as well as the red blood cell precursor cells in the bone marrow. As part of the cytoplasmic membrane of the red blood cell, this bacteria membrane complex now functions as a hapten complex.
Because these bacteria cells are now, for the first time without the capsule protection, an immune response can be launched. This reaction gives rise to the formation of a Type Il immune response and ends in the full-blown auto-immune haemolitic anaemia with subsequent haemolysis of red blood cells and ends in severe anaemia with ultimate congestive cardiac failure and death.
It is an object of this invention to provide a composition which will at least partially alleviate problems with operation of the immune system.
In accordance with this invention there is provided a composition to assist immune response comprising a combination of oils selected from Thyme,
Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John’s Wort oils together with Humic Acid. :
The invention further provides for the composition to include amino acids; preferably Arginine and/or Ornithine; and for the Humic Acid to be natural Humic
Acid.
Further features of the invention provide for the oils to be deposited on the Humic
Acid; and for the oils to be dissolved in a solvent, preferably Ethanol, and sprayed onto the Humic Acid.
Further features of the invention provide for the composition to be administered as a food additive or as a water soluble solution added to drinking water. The composition may also be provided and administered as capsules. The dosage is * calculated at 3 to 5g per 100 Kg live body weight per day.
In accordance with another aspect of this invention there is provided a use of the above defined composition in the manufacture of a medicament for the treatment of an immune response deficiency.
The composition in accordance with this invention is made up of a combination of natural essential oils and natural Humic Acid. The oils are selected from Thyme,
Marjoram, Lavender, Rosemary, Cinnamon, Basil, and St John’s Wort oil. The composition will preferably include all of these oils. This combination is formulated to cover aspects of anti-inflammation, anti-bacterial, anti-parasitic,
anti-viral as well as anti-depressive effects that may arise from the immune suppressive syndrome already mentioned.
The oils are dissolved in an alcohol, preferably 96% Ethanol, and sprayed onto the granular Humic Acid. A residue of the oils remains on evaporation of the
Ethanol. Amino acids in the form of Arginine and Ornithine are then also added.
The composition can be used in any animal type as well as in humans to stimulate and activate a normal immune response after a period of suppression, and to help normalize the DMI (dormant macrophage index).
The Humic Acid in combination with some of the oils has the ability to activate immune cellular response. In particular, it can rectify and normalize cellular responses in T-helper cell function in some cases and again T-suppressor cell function in other cases. The trigger for either T-helper or T-suppressor cell stimulation will be determined by the specific etiology of the immune system : suppression and to reinstate and rectify normal immune responses. There is normally a balance between effector cells and imbalances occur when either the
T-helper function on the one hand is stimulated out of proportion, and again when T-suppressor function is over stimulated. The T-helper 2 cell is active in determining either T-helper or T-suppressor at a specific time, and it is this function that can be influenced by Humic acid/oil combination.
The amino acids aid the fatty changes associated with this syndrome of deficient immune response to rectify normal bone marrow cellularity as well as the restoration of the normal response. In other words, the fatty changes associated with this syndrome are reversed.
The administration of the treatment can either be as a food additive or as a water soluble solution added to the daily intake of water. Alternatively, the composition é may be provided and administered as capsules. The dosage is calculated as 3 to : 5g per 100 Kg live body weight per day.
The DMI (dormant macrophage index) in the bone marrow, which is explained in more detail below, can be used to determine the efficacy of the composition in the treatment of immune suppressed animals.
The method as it is herein described has been carried out on chickens. Bone marrow is taken from the proximal end of the femur head area. This area is used because the anatomical blood supply here is limited. Accordingly, it would host the largest amount of bacteria. The relative low oxygen supply to this part of the bone area through the nutrient artery gives facultative anaerobic bacteria a greater chance to grow and survive.
Using glass slides, microscopic blood smears are made. The smears are stained with any Romanofsky stain to differentiate and identify the different bone marrow cells. Lying freely in the bone marrow are all the different red blood as well as the white blood cell precursors and mature blood cells. Also present are effector cells as part of the immune system. These cells have the ability to engulf the bacteria.
Because the bacteria in question have not been opsonified by antibodies previously produced by the immune system, they are not eliminated through the process of lysosomal enzyme breakdown in phagosomes. The bacteria lie dormant within the cytoplasm of these cells, in this case the macrophage cells.
This complex cell is now called the DMI (dormant macrophage index), as referred to previously, within the bone marrow and represents the grade of the dormant infection within this organ system.
The normal value of these DMI cells can be from 5 to 8%. Anything higher than this value indicates a dormant infective state. Samples from a population can thus be used to test for improvements from treatment with the composition.
Activation of the pathogens referred to will normally only be triggered when the bone marrow is subjected to any stress situation. This is thus also a tool to predict a potential future infection when the bone marrow is under a stressful assault. Without looking at such a sample it would not be anticipated that there is anything wrong in the bone marrow or that there may be the potential of elevation to an infective state. That is why up to now erratic infections would appear from nowhere and without any explanation to the origin of the infection, and generally after a period of stress.
The composition of this invention is directed mainly to rectify and reinstate normal biological processes into the immunological system and eradicate previously induced abnormal chemical entities. The unscrupulous chronic use of antibiotics and totally erratic immunization procedures all add up to totally suppress the immune system and leave it susceptible to infection. It is therefore important to normalize physiological biological systems, through the use of natural organic preparations, and reinstate normal standards of the self ability of all living organisms to launch an immune response and rectify the intrusion of infective agents.
Claims (22)
1. A composition to assist immune response comprising a combination of oils selected from Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John’s Wort oils together with Humic Acid.
2. A composition as claimed in claim 1 which includes an amino acid.
3. A composition as claimed in claim 2, in which the amino acid is Arginine and/or Ornithine.
4. A composition as claimed in any of claims 1 to 3 in which the Humic Acid is natural Humic Acid.
5. A composition as claimed in any one of claims 1 to 4 in which the oils are deposited onto the Humic Acid.
6. A composition as claimed in claim 5 in which the oils are dissolved in a solvent and sprayed onto the Humic Acid.
7. A composition as claimed in claim 6 in which the solvent is Ethanol.
8. A composition as claimed in any of claims 1 to 7 which is administered as a food additive.
9. A composition as claimed in any of claims 1 to 7 which is administered as a water soluble solution added to drinking water.
10. A composition as claimed in any of claims 1 to 7 which is administered in capsules.
11. A composition as claimed in any of claims 1 to 10 which is administered as a dosage calculated at 3 to 5g per 100 Kg live body weight per day.
12. Use of a composition comprising a combination of oils selected from Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John’s Wort oils together with Humic Acid in the manufacture of a medicament for the treatment of an immune response deficiency.
13. Use as claimed in claim 12 in which the composition includes an amino acid.
14. Use as claimed in claim 13 in which the amino acid is Arginine and/or Ornithine.
15. Use as claimed in any of claims 12 to 14 in which the Humic Acid is natural Humic Acid
16. Use as claimed in any of claims 12 to 15 in which the oils are deposited on the Humic Acid.
17. Use as claimed in claim 16 in which the oils are dissolved in a solvent and sprayed onto the Humic Acid.
18. Use as claimed in claim 17 in which the solvent is Ethanol.
19. Use as claimed in any of claims 12 to 18 in which the medicament is administered as a food additive.
20. Use as claimed in any of claims 12 to 18 in which the medicament is administered as a water soluble solution added to drinking water.
A \ hd - « " ’
21. Use as claimed in any of claims 12 to 18 in which the medicament is administered in capsules. :
22. Use as claimed in any of claims 12 to 21 in which the medicament is administered as a dosage calculated at 3 to 5g per 100 Kg live body weight per day. : DATED THIS 11™ DAY OF JULY 2007 DESSIN N DE BEER FOR THE APPLICANT
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200705708A ZA200705708B (en) | 2006-07-11 | 2007-07-11 | A composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200605692 | 2006-07-11 | ||
| ZA200705708A ZA200705708B (en) | 2006-07-11 | 2007-07-11 | A composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200705708B true ZA200705708B (en) | 2008-12-31 |
Family
ID=40942209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200705708A ZA200705708B (en) | 2006-07-11 | 2007-07-11 | A composition |
Country Status (1)
| Country | Link |
|---|---|
| ZA (1) | ZA200705708B (en) |
-
2007
- 2007-07-11 ZA ZA200705708A patent/ZA200705708B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Effect of in ovo feeding of l-arginine on the hatchability, growth performance, gastrointestinal hormones, and jejunal digestive and absorptive capacity of posthatch broilers | |
| CN107075473B (en) | Differentiation-induced cell population in which undifferentiated cells are removed, uses thereof, and methods for producing same | |
| JP6898989B2 (en) | A feed composition for the prevention or treatment of acute hepatopancreatic necrosis (AHPND) or white spot disease syndrome (WSS) containing Bacillus subtilis strain as an active ingredient. | |
| JPWO2005030938A1 (en) | Fermentation and culture method, plant fermented extract, plant fermented extract powder and blended plant fermented extract | |
| CN105008525A (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| US11497197B2 (en) | Methods for enhancing poultry growth and performance | |
| Zhang et al. | Effects of fecal bacteria on growth, digestive capacity, antioxidant capacity, intestinal health of large yellow croaker (Larimichthys crocea) larvae | |
| JP2021183608A (en) | Compositions and methods for modulating and/or stimulating immune responses in human and/or animal | |
| SK94297A3 (en) | New applications of lysozyme dimer | |
| CN108165522B (en) | Embryonic-period supplement for improving quality of broiler chickens and promoting early growth and application thereof | |
| CN113413455B (en) | Immunity enhancing composition and application thereof | |
| ZA200705708B (en) | A composition | |
| CN112891363B (en) | New Zealand vitexin 2 and new Zealand vitexin 3 application | |
| Bryan et al. | The influence of indigestible protein on broiler digestive tract morphology and caecal protein fermentation metabolites | |
| Volkov et al. | History of highly pathogenic avian influenza eradication in russian federation in 2016–2017 | |
| RU2410425C1 (en) | Culture medium for growing mycobacterium tuberculosis | |
| Ameji et al. | Outbreak of highly pathogenic avian influenza subtype H5N8 in two multi-age chicken farms in Jos, Plateau State, Nigeria | |
| CN114736875B (en) | Riemerella anatipestifer phage, phage composition and application thereof | |
| CN103550286B (en) | A kind of infectious bursal disease live-vaccine effervescent tablet immunological adjuvant | |
| Ching et al. | Effects of Pleurotus pulmonarius stalk waste extract‐supplemented feed on the immune responses of red hybrid tilapia Oreochromis sp. following challenge with pathogen‐associated molecular patterns | |
| Hassan et al. | Immune indicators, growth, hematological parameters, liver enzymes and kidney function of growing rabbits as affected by bee pollen and/or mannan-oligosaccharides | |
| Coates | The biologists’ debt to the domestic fowl | |
| El‐Shater et al. | Effect of in‐ovo inoculation of betaine on hatchability, serum antioxidant levels, muscle gene expression and intestinal development of broiler chicks | |
| Pappas | Effects of Vitamin Antimetabolites on Lebistes Reticulatus | |
| CN112933074A (en) | New application of cynarin |